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Multiple sclerosis (MS) is an autoimmune disease with both genetic and environmental risk factors. Recent
studies indicate that childhood and adolescent obesity double the risk of MS, but this association may reﬂect
unmeasured confounders rather than causal effects of obesity. We used separate-sample Mendelian ran-
domization to estimate the causal effect of body mass index (BMI) on susceptibility to MS. Using data from
non-Hispanic white members of the Kaiser Permanente Medical Care Plan of Northern California (KPNC) (2006–
2014; 1,104 cases of MS and 10,536 controls) and a replication data set from Sweden (the Epidemiological
Investigation of MS (EIMS) and the Genes and Environment in MS (GEMS) studies, 2005–2013; 5,133 MS
cases and 4,718 controls), we constructed a weighted genetic risk score using 97 variants previously established
to predict BMI. Results were adjusted for birth year, sex, education, smoking status, ancestry, and genetic predic-
tors of MS. Estimates in KPNC and Swedish data sets suggested that higher genetically induced BMI predicted
greater susceptibility to MS (odds ratio = 1.13, 95% conﬁdence interval: 1.04, 1.22 for the KPNC sample; odds
ratio = 1.09, 95% conﬁdence interval: 1.03, 1.15 for the Swedish sample). Although the mechanism remains
unclear, to our knowledge, these ﬁndings support a causal effect of increased BMI on susceptibility to MS for the
ﬁrst time, and they suggest a role for inﬂammatory pathways that characterize both obesity and the MS disease
process.
body mass index; genetic instrumental variables; Mendelian randomization; multiple sclerosis; obesity
Abbreviations: BMI, body mass index; CI, conﬁdence interval; DRB1, antigen D–related β1 subunit; EIMS, Epidemiological
Investigation of MS; FTO, fat mass and obesity–associated gene; GEMS, Genes and Environment in MS; GERA, Genetic
Epidemiology Research on Aging; GRS, genetic risk score; GWAS, genome-wide association study; HLA, human leukocyte
antigen; KPNC, Kaiser Permanente Medical Care Plan of Northern California; MS, multiple sclerosis; MR, Mendelian
randomization; OR, odds ratio; wGRS, weighted genetic risk score.
Multiple sclerosis (MS) is characterized as an immune
system–mediated demyelinating disorder with widespread
axonal degeneration occurring throughout the disease pro-
cess (1), resulting in signiﬁcant disability and decreased
quality of life. Strong evidence supports the contribution of
both genetic and environmental factors to MS susceptibility
(2). Investigators have identiﬁed several genetic variants,
including the *15:01 allele of the human leukocyte antigen
(HLA) antigen D–related β1 subunit (DRB1) gene (HLA-
DRB1*15:01) within the major histocompatibility complex
(3, 4) and 110 non-HLA variants (4). Environmental risk
factors associated with MS include exposure to tobacco
smoke and low levels of vitamin D (5).
Recently, obesity has emerged as a signiﬁcant risk factor
for MS. Associations between MS and body mass index
(BMI) at age 18 years (6), at age 20 years (7), and during
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the ages 20–29 years (8) have been observed; individuals
with a BMI of at least 30 demonstrated a more than 2-fold
increased risk of MS compared with persons with a BMI of
at least 18.5 and less than 21 (within the normal weight
range according to BMI). The relationship was also con-
ﬁrmed using retrospective assessments of body size, with
the strongest association being observed at age 25 years
(9). Additionally, childhood obesity and risks of both pedi-
atric (10) and later-onset (11) MS have been reported.
Research has also indicated that HLA genes interact with
BMI during adolescence to increase the risk of MS (12).
Although investigators have hypothesized about various
mechanisms that might mediate the association between
obesity and MS, a causal relationship remains to be con-
ﬁrmed. Observational ﬁndings cannot exclude the possi-
bility that weight change preceding a diagnosis may be
associated with a prodromal period of disease—that is, a
decrease in physical activity due to MS symptoms before
diagnosis may lead to increased weight and thus bias
ﬁndings.
The genetic basis of obesity has been demonstrated by
studies revealing multiple variants throughout the genome
associated with obesity-related traits. A recent genome-
wide association study (GWAS) identiﬁed 97 signiﬁcant
loci that explained 2.7% of the variance associated with
BMI (13). To our knowledge, no study has examined the
relationship between genes associated with BMI and MS.
Using genetic predictors of an exposure of interest as inde-
pendent variables in an observational study corresponds
with a “Mendelian randomization” (MR) study design,
which avoids bias from reverse causation and potential
confounders, therefore strengthening causal inferences
with complex exposures such as BMI.
We applied instrumental variable analysis in an MR
framework to estimate the causal relationship between BMI
and susceptibility to MS using a BMI genetic risk score
(GRS) comprising 97 variants (13) in 2 populations. We
further examined whether any variants appeared to directly
inﬂuence MS via mechanisms unrelated to BMI.
METHODS
KPNC participants
MS cases and controls were recruited from members of
Kaiser Permanente Medical Care Plan of Northern California
(KPNC). KPNC is an integrated health care–services deliv-
ery system with 3.2 million members that covers about
25%–30% of the population of a 22-county service area and
is the largest health-care provider in Northern California.
Membership is objectively representative of the general pop-
ulation; however, persons in impoverished neighborhoods
are underrepresented (14).
This study was restricted to individuals with self-identiﬁed
white (non-Hispanic) race/ethnicity, the population with the
highest prevalence of MS. Eligible KPNC cases were deﬁned
as individuals who had received a diagnosis of MS from a
neurologist (International Classiﬁcation of Diseases, Ninth
Revision, code 340.x; 94.7% of cases had at least 2 MS diag-
noses by a neurologist), were aged 18–69 years, and were
members of KPNC at initial contact. Recruitment began in
mid-2006; a total of 3,293 potential MS cases were re-
viewed by KPNC neurologists, who approved contact with
2,823 (86%) at the time of the data freeze (August 2014).
Diagnoses were validated using published diagnostic crite-
ria and review of electronic health records (15, 16).
Controls were current KPNC members without a diagno-
sis of MS or a related condition (optic neuritis, transverse
myelitis, or demyelination disease), conﬁrmed through
electronic records, and who reported white (non-Hispanic)
race/ethnicity. Controls were matched to cases on age, sex,
and zip code. Potential study participants were contacted
by mail, with a follow-up phone call to explain the study
and procedures. The participation rate was approximately
80% for cases and 66% for controls. Genetic data were
available for approximately 80% of study participants.
Additional controls included individuals in the Genetic
Epidemiology Research on Aging (GERA) cohort who
participated in the KPNC Research Program on Genes,
Environment, and Health. The KPNC program was estab-
lished to research genetic and environmental inﬂuences
on health and disease and is described in more detail else-
where (17). Recruitment began in 2007. GERA cohort
members gave broad, written consent and provided a
saliva sample for DNA extraction (17). Approximately
77% of the cohort returned completed consent forms for
placement in the Database of Genotypes and Phenotypes,
which resulted in a ﬁnal sample size of 78,486 partici-
pants. From these participants, we selected a subset of
12,605 self-reported non-Hispanic white individuals
without evidence of MS in their electronic health records
and matched them to cases on sex and age (within 2
years) at a 10:1 ratio. Study protocols were approved by
the institutional review boards of KPNC and the
University of California, Berkeley.
Swedish participants
Data were collected from 2 population-based case-control
studies, one a study of MS incidence (Epidemiological
Investigation of MS (EIMS)) and the other a study of MS
prevalence (Genes and Environment in MS (GEMS)). The
EIMS Study (2005–2013) inclusion criteria were being aged
16–70 years, having been diagnosed with MS according to
the McDonald criteria (15, 16) within the past 2 years, and
having the ability to understand the Swedish language.
GEMS Study participants were identiﬁed from the Swedish
National MS registry, fulﬁlled the McDonald criteria (15, 16),
and were recruited during 2009–2011. For both studies, con-
trols were randomly chosen from the population register and
matched to cases by sex, age at inclusion in the study, and
region of residence. Two controls were matched to each
case in the EIMS Study, and 1 control was matched to each
case in the GEMS Study. All participants in the EIMS Study
were distinct from those in the GEMS Study. Ethical
approval for both studies was obtained from the Regional
Ethical Review Board in Stockholm at the Karolinska
Institutet, and participants provided written informed con-
sent. Details on the study’s design have been published else-
where (7, 12). The participation rate in the EIMS Study was
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92% for cases and 67% for controls, and participation in the
GEMS Study was 82% for cases and 66% for controls.
Genotyping data were available for 75% of EIMS partici-
pants and 91% of GEMS participants. Data for 6,335 cases
and 5,762 controls were available from the Swedish studies.
Exposure assessment
KPNC participants completed a computer-assisted tele-
phone interview administered by trained staff interviewers
and composed of questions related to various events and
exposures, as described elsewhere (8). GERA controls
completed a survey related to health behaviors, sociode-
mographic information, and diagnoses. KPNC study parti-
cipants reported their highest and lowest (nonpregnancy)
weights at ages 20–29 years. The mean weights of the
KPNC participants during their twenties were calculated
by averaging the highest and lowest weights reported.
GERA controls reported their weight at age 18 years.
Exposure assessment in the Swedish studies was done
through an extensive questionnaire that participants com-
pleted at home. Incomplete questionnaires were completed
by mail or telephone. The questionnaire covered demo-
graphic and environmental/lifestyle factors, including cur-
rent height and weight at age 20 years. The details have
been provided elsewhere (7, 12).
Each participant’s BMI was calculated by dividing
weight in kilograms (or mean weight for KPNC partici-
pants) by squared height in meters (reported at time of inter-
view). KPNC and Swedish participants provided blood or
saliva samples for genotyping. For details on platforms and
quality control, see the Appendix.
Statistical analyses
A weighted genetic risk score (wGRS) for MS risk var-
iants was calculated for each individual. The GRS weights
risk alleles by the logarithm of the odds ratio for each of
the 110 non-HLA loci for MS susceptibility identiﬁed
through the most recent MS GWAS (4). The wGRS was
calculated by multiplying the number of risk alleles for
each locus by the weight for that variant, and then taking
the sum across the 110 loci. One variant for KPNC
(rs201202118) and 2 variants for the Swedish studies
(rs2028597, rs6874308) were missing.
The BMI GRS was calculated by multiplying the num-
ber of risk alleles for each BMI-related locus (13) by the
weight (deﬁned as the beta coefﬁcient from the BMI
GWAS) for that variant and then taking the sum across the
97 loci. One variant was missing for the Swedish data set
(rs2245368). To correct for the fact that the GWAS by
Locke et al. (13) was based on a residualized BMI trans-
formed into standard deviation units—and to express this
weight in terms of BMI units—we multiplied by a constant
of 4.95. This value was estimated using the regression anal-
ysis among persons of European descent in the Health and
Retirement Study, as reported in the GWAS (13). With this
transformation, each unit change in the weighted BMI
GRS corresponds with an anticipated 1-unit change in
BMI, allowing for direct interpretation of the estimates as
the estimated effect of a unit increase in the genetically pre-
dicted BMI on the odds of MS (BMI GRS ranges: 8.64–
14.52 in KPNC and 8.41–14.33 in Sweden).
After quality control and removal of population outliers,
a total of 2,163 individuals (1,104 cases and 804 controls)
with genetic data were available from the KPNC sample,
as well as an additional 9,732 controls from the GERA
Study, for a total of 1,104 cases and 10,536 controls. The
ﬁnal data set for Swedish participants included 5,133 cases
and 4,718 controls. Demographic differences between
cases and controls were compared using χ2 tests and inde-
pendent sample t tests where appropriate. Linear regression
analysis was used to demonstrate the association of each
GRS with BMI during young adulthood (during ages 20–
29 years for KPNC, at age 18 years for GERA, and at age
20 years for the Swedish studies) and to test the assumption
that the BMI GRS is not associated with confounding fac-
tors. MR analysis was performed by regressing MS case
status on BMI GRS.
In addition, we evaluated evidence that any of the BMI
variants had a direct effect on MS, implying a violation of
the MR assumption that there is no direct effect of the
instrument on the outcome (18). Direct effects were ana-
lyzed using regression-based mediation to estimate the con-
trolled direct effect for changes in exposure level (19).
Analyses examined 97 BMI variants, measuring the effect
on MS status (case/control) of having no alleles that
increase BMI risk (a = 0) versus having 2 risk alleles
(a = 1) at each locus. The mediator was speciﬁed as BMI
during young adulthood and set to 22.0, or the mean of the
“normal” healthy BMI range as deﬁned by the World
Health Organization. Analyses were bootstrapped with 100
replications, and estimates from both data sets (KPNC and
Swedish studies) were used to conduct a random-effects
meta-analysis.
Odds ratios with 95% conﬁdence intervals were esti-
mated. All analyses controlled for established risk factors
associated with MS susceptibility that were measured in
both the KPNC and Swedish populations, including sex,
year of birth, smoking status, college education, HLA-
DRB1*15:01 status, wGRS of non-HLA MS risk var-
iants, and ancestry as derived from principal components
analysis. Swedish analyses additionally controlled for
study type (EIMS vs. GEMS). Analyses were conducted
in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink),
STATA (StataCorp LP, College Station, Texas), and R
(R Foundation for Statistical Computing, Vienna, Austria).
This study was focused on a single hypothesis established
a priori: BMI is causally associated with MS as repre-
sented by a BMI GRS. Therefore, we report 95% conﬁ-
dence intervals and use an α = 0.05 threshold for 2-sided
tests of statistical signiﬁcance.
RESULTS
There were signiﬁcant differences between cases and
controls with respect to smoking status, college graduation,
HLA-DRB1*15:01 status, and wGRS in the KPNC and
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Table 1. Demographic and Disease Characteristics of Non-Hispanic White Persons Diagnosed With Multiple Sclerosis and Controls in Northern California (2006–2014) and Sweden
(2005–2013)a
Characteristic
KPNC Sweden
MS Cases (n = 1,104) Controls (n = 10,536)
P Valueb P Valuec
MS Cases (n = 5,133) Controls (n = 4,718) P
Valueb
P
ValuecNo. % Mean (SD) No. % Mean (SD) No. % Mean (SD) No. % Mean (SD)
Birth year 1958 (8.93) 1958 (8.95) 0.67 0.72 1960 (13.38) 1961 (13.53) <0.001 0.38
Sex 0.29 0.83 <0.001 0.27
Female 882 79.89 8,555 81.20 3,741 73.17 3,592 76.13
Male 222 20.11 1,981 18.80 1,392 27.22 1,126 23.87
Smoker <0.001 <0.001 <0.001 0.003
Never smoker 555 50.36 7,004 67.93 2,163 42.30 2,371 50.25
Ever smoker 547 49.64 3,307 32.07 2,853 55.80 2,146 45.49
College graduate <0.001 0.02 0.001 0.10
Yes 488 44.20 3,677 35.84 3,725 72.85 3,279 69.50
No 616 55.80 6,583 64.16 1,397 27.32 1,433 30.37
HLA-DRB1*15:01
status
<0.001 0.98 <0.001 0.73
0 alleles 518 46.92 7,752 73.60 2,144 41.93 3,321 70.39
1–2 alleles 586 53.08 2,781 26.40 2,989 58.46 1,397 29.61
wGRS of non-HLA
risk variants
12.86 (0.68) 12.47 (0.68) <0.001 0.03 12.48 (0.67) 12.08 (0.69) <0.001 0.05
BMI in young
adulthoodd
22.97 (4.37) 21.47 (3.30) <0.001 <0.001 21.97 (3.56) 21.68 (3.20) <0.001 <0.001
BMI GRS 11.55 (0.82) 11.47 (0.81) 0.002 11.56 (0.82) 11.50 (0.81) 0.0002
Abbreviations: BMI, body mass index; GRS, genetic risk score; HLA, human leukocyte antigen; HLA-DRB1*15:01, *15:01 allele of the human leukocyte antigen (HLA) antigen D–related
β1 subunit (DRB1) gene; KPNC, Kaiser Permanente Medical Care Plan of Northern California; MS, multiple sclerosis; SD, standard deviation; wGRS, weighted genetic risk score.
a Race/ethnicity was deﬁned by genetic ancestry. Percentages may not total 100 due to missing values.
bP value from a t test (continuous variables) or χ2 test (categorical variables) of the difference between MS cases and controls for each cohort (KPNC and Swedish studies).
cP value for linear regression analysis of BMI GRS and each variable.
d BMI in young adulthood was deﬁned as BMI at age 18 years (Genetic Epidemiology Research on Aging), during ages 20–29 years (KPNC), or at age 20 years (Sweden) and was
calculated as weight (kg)/height (m)2.
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Swedish studies (Table 1). BMI during young adulthood
was signiﬁcantly higher in cases than in controls, as was
the BMI GRS, in both data sets. The BMI GRS was associ-
ated with college education and wGRS in the KPNC mem-
bers and with smoking in both populations. The association
between the BMI GRS and BMI in young adulthood was
similar in men and women (Table 2). For every unit in-
crease in the GRS, BMI in young adulthood increased on
average 0.64 units in the KPNC sample and 0.54 units in
the Swedish data set, where a value of 1.0 would indicate
that the effect of the variants on BMI in our populations
was the same as the effect in the GWAS from which the
weights were drawn.
The BMI GRS signiﬁcantly predicted odds of MS after
controlling for sex, year of birth, education, ancestry, smoking
status, wGRS, and number ofHLA-DRB1*15:01 alleles in the
KPNC sample participants (odds ratio (OR) = 1.13, 95% con-
ﬁdence interval (CI): 1.04, 1.22; Table 3 and Figure 1).
Similar results were found for the Swedish studies after con-
trolling for the same covariates plus study type (OR = 1.09,
95% CI: 1.03, 1.15) and in the meta-analysis of the ﬁndings
from both studies (OR = 1.10, 95% CI: 1.05, 1.15). No evi-
dence of heterogeneity between populations was observed
(I2= 0.0%; P= 0.47).
Results stratiﬁed by sex showed a signiﬁcant associa-
tion in women but not men among the KPNC participants
(for women, OR = 1.14, 95% CI: 1.04, 1.25; for men,
OR = 1.11, 95% CI: 0.92, 1.33) and in the Swedish studies
(for women, OR = 1.09, 95% CI: 1.03, 1.16; for men,
OR = 1.08, 95% CI: 0.97, 1.20). However, the wide
Table 2. Association Between Body Mass Index–Related Genes and Self-Reported Body Mass Index in Young
Adulthooda, Northern California (2006–2014) and Sweden (2005–2013)
FTO and Genetic
Risk Score
KPNC Sweden
Coefﬁcient 95% CI R2, % Coefﬁcient 95% CI R2, %
FTO only 0.29 0.20, 0.39 0.4 0.27 0.18, 0.36 0.3
Women 0.23 0.13, 0.34 0.2 0.29 0.18, 0.40 0.4
Men 0.51 0.31, 0.72 1.2 0.22 0.06, 0.38 0.2
BMI GRS 0.64 0.56, 0.72 2.3 0.54 0.45, 0.63 1.5
Women 0.61 0.53, 0.70 2.1 0.51 0.40, 0.61 1.3
Men 0.74 0.57, 0.91 3.6 0.61 0.45, 0.76 2.3
Abbreviations: BMI, body mass index; CI, conﬁdence interval; FTO, fat mass and obesity–associated gene;
GRS, genetic risk score; KPNC, Kaiser Permanente Medical Care Plan, Northern California Region.
a The results of linear regression analyses of BMI-related genes and self-reported BMI in young adulthood were
all signiﬁcant (P < 0.001). BMI in young adulthood was deﬁned as BMI at age 18 years (Genetic Epidemiology
Research on Aging), during ages 20–29 years (KPNC), or at age 20 years (Sweden) and was calculated as weight
(kg)/height (m)2.
Table 3. Results From a Multivariate Regression Analysis of the Effect of Body Mass Index on Susceptibility to
Multiple Sclerosis Carried Out Using Body Mass Index Genetic Risk Scores, Northern California (2006–2014) and
Sweden (2005–2013)
Variable
KPNC Sweden
OR 95% CI P Valuea OR 95% CI P Valuea
BMI GRS 1.13 1.04, 1.22 0.004 1.09 1.03, 1.15 0.002
Female sex 0.94 0.80, 1.12 0.50 0.80 0.72, 0.89 <0.001
Birth year 1.00 1.00, 1.01 0.07 1.01 1.00, 1.01 0.006
No college education 0.77 0.67, 0.88 <0.001 0.91 0.83, 1.01 0.07
Ever smoker 2.02 1.76, 2.31 <0.001 1.49 1.36, 1.62 <0.001
HLA-DRB1*15:01 status 3.55 3.10, 4.06 <0.001 3.43 3.14, 3.76 <0.001
wGRS for non-HLA MS risk variants 2.32 2.10, 2.57 <0.001 2.36 2.20, 2.52 <0.001
Abbreviations: BMI, body mass index; CI, conﬁdence interval; GRS, genetic risk score; HLA, human leukocyte
antigen; HLA-DRB1*15:01, *15:01 allele of the human leukocyte antigen (HLA) antigen D–related β1 subunit
(DRB1) gene; KPNC, Kaiser Permanente Medical Care Plan of Northern California; MS, multiple sclerosis; OR,
odds ratio; wGRS, weighted genetic risk score.
aP value for a logistic regression model that adjusted for ancestry using principal components. For the Swedish
studies, the model additionally controlled for study type.
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conﬁdence intervals suggest that this is consistent with
chance given the smaller sample of male participants.
The meta-analysis results for the direct effect estimates
showed that 5 variants associated with increased BMI in
the literature exhibited a signiﬁcant controlled direct effect
on MS susceptibility after adjustment for covariates
(Table 4). Four variants were positively associated with
MS, and 1 variant was inversely associated with MS.
Given the potential violation of the assumption that there
is no direct effect of the instrument on the outcome, we
repeated the MR analysis using a BMI GRS that excluded
the 5 variants for which we found evidence of a possible
direct effect on MS. The ﬁndings demonstrated a consis-
tent, signiﬁcant association between the revised 92-variant
BMI GRS and MS after controlling for covariates in both
KPNC and Swedish participants (for KPNC, OR = 1.13,
95% CI: 1.04, 1.23; for the Swedish studies, OR = 1.09,
95% CI: 1.03, 1.15).
We also adjusted the MR analysis of 92 variants for
BMI during young adulthood to examine evidence that the
GRS had effects on MS that were not mediated by BMI.
This adjustment attenuated our ﬁndings and reduced the
signiﬁcance of the association in the KPNC participants
(OR = 1.05, 95% CI: 0.97, 1.15) and the Swedish data set
(OR = 1.06, 95% CI: 1.00, 1.12).
In order to test the assumptions of the MR model for the
BMI GRS, we conducted overidentiﬁcation tests to evalu-
ate the null hypothesis that effect estimates from multiple
instrumental variables are identical (18). The 92 variants
without a direct effect on the outcome were randomly split
into 5 separate instruments. Estimates suggested the same
direction of causal effect, with odds ratios ranging from
1.04 to 1.22 in KPNC participants and from 1.01 to 1.25 in
the Swedish studies.
DISCUSSION
To our knowledge, this study was the ﬁrst to examine the
relationship between BMI and MS using MR. We also pres-
ent novel results suggesting that 5 variants previously estab-
lished to predict BMI may have direct effects on MS. None
of the direct effect variants or genes—and none of the var-
iants or genes from the 97 BMI-related variants analyzed
by Locke et al.—overlap with the established 110 non-
HLA MS risk loci. Our results suggest a causal association
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Figure 1. Odds ratios for the effect of body mass index (BMI) on susceptibility to multiple sclerosis (MS), obtained using genetic variants as
instrumental variables in populations in Northern California (2006–2014) and Sweden (2005–2013). Results were adjusted for smoking, educa-
tion, birth year, HLA-DRB1*15:01 status, weighted genetic risk score (GRS) for non-HLA MS-risk variants, genetic ancestry, and sex. Results
from Sweden were additionally adjusted for study type. Odds ratios were signiﬁcant (P < 0.01) for fat mass and obesity–associated gene (FTO)
Sweden, BMI GRS Kaiser Permanente Medical Care Plan of Northern California (KPNC), BMI GRS Sweden, and meta-analysis. Bars, 95%
conﬁdence interval. HLA-DRB1*15:01, *15:01 allele of the human leukocyte antigen (HLA) antigen D–related β1 subunit (DRB1) gene.
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between higher BMI and MS susceptibility, and they iden-
tify new genetic variants that may directly inﬂuence MS
onset.
The most widely studied obesity-related genetic variant
is the fat mass and obesity–associated gene (FTO) (20, 21).
Variants in FTO have been found to be associated with var-
ious cancers (22–24), Alzheimer’s disease and dementia
(25), reduced brain volume in healthy elderly individuals
(26), and cognitive decline in healthy adults (27). Although
one study found that an FTO risk allele was correlated with
signiﬁcantly increased homocysteine levels in MS cases
compared with controls (28), to our knowledge, no study
has previously examined the relationship between BMI
genes and MS. Our study found that FTO alone slightly
increased the risk of MS and that there was some evidence
of a direct effect of FTO on MS susceptibility.
Since the discovery of FTO, additional genes have been
found to be associated with obesity-related traits. In a
recent study, Locke et al. (13) reported 97 variants, of
which 56 were novel, in the largest GWAS meta-analysis
of BMI to date. Previous studies using a subset of these
variants improved prediction of BMI and obesity beyond
demographic, geographic, and socioeconomic status infor-
mation (29). This subset of variants has also been found to
have a signiﬁcant inﬂuence on BMI during childhood, ado-
lescence, and adulthood in a longitudinal cohort (30).
Thus, the variants seem to confer a life-course risk of obe-
sity rather than risk at one time point. We found that a
score including the 97 BMI variants was signiﬁcantly asso-
ciated with MS in 2 populations. Effect estimates were con-
sistent with estimates based on FTO only, as would be
expected if all these variants inﬂuenced MS via a common
pathway—for example, BMI. This perspective is also sup-
ported by our overidentiﬁcation tests, which found no sig-
niﬁcant difference in effects across 5 arbitrary groupings.
We also found very similar estimates when we used all 97
variants or excluded 5 with some evidence of a direct
effect. These 3 lines of evidence suggest that although
some of the genetic variants may have small direct effects
on MS, there is probably a common pathway to MS medi-
ated by BMI.
There are several hypotheses linking obesity and autoim-
mune diseases, including MS. T-helper 17 cells, which
secrete interleukin-17, have recently been implicated in the
pathogenesis of autoimmune disease, and obesity may pre-
dispose induction of T-helper 17 cells via an interleukin-6–
dependent process leading to exacerbation of inﬂammatory
diseases such as MS (31). The intestinal immune response
has also been hypothesized to explain the association
between obesity and MS; an imbalance of T-helper 17 and
T-regulatory cells may lead to alteration of the intestinal
microbiome (32, 33). It has also been shown that vitamin
D deﬁciency is prevalent among obese individuals (34).
Given that vitamin D regulates immune response (35), this
may have implications for MS susceptibility. Additionally,
white adipose tissue is an essential endocrine organ that se-
cretes adipokines (e.g., interleukin-6, tumor necrosis factor
alpha, leptin, adiponectin), which are involved in immune
and inﬂammatory processes and contribute to a low-grade
inﬂammatory state in obese individuals (36). Certain adi-
posity genes, some of which overlap with genes in the
BMI GRS used in this study, have been shown to be asso-
ciated with age of menarche (37), and adipokines such as
leptin are up-regulated by ovarian sex steroids. Lastly, a
recent study demonstrated genetic evidence for connections
between motor deﬁcits, obesity, and neurological disorders
(38). More research is needed to identify the biological me-
chanisms mediating the association between BMI and MS,
which has the potential to contribute to our understanding
of other autoimmune and neurological diseases.
A major strength of this study was the large sample size
and the statistical power to demonstrate an association using
Table 4. Signiﬁcant Controlled Direct Effects of Gene Variants Related to Body Mass Index on Susceptibility to Multiple Sclerosis, Northern
California (2006–2014) and Sweden (2005–2013)
Single-Nucleotide
Polymorphism Chromosome Gene
KPNC Sweden Meta-Analysis
OR 95% CI P Valuea OR 95% CI P Valuea OR 95% CI
Signiﬁcant Controlled Direct Effect Associated With an Increased Risk of MS
rs11126666 2 KCNK3 1.20 0.96, 1.48 0.002 1.13 0.93, 1.29 0.001 1.15 1.01, 1.30
rs2112347 5 POC5 1.05 0.83, 1.28 0.32 1.16 1.04, 1.30 <0.001 1.13 1.02, 1.25
rs1558902 16 FTO 1.13 0.94, 1.36 0.01 1.17 1.02, 1.35 <0.001 1.16 1.03, 1.28
rs7243357 18 GRP 1.14 0.80, 1.49 0.06 1.26 1.06, 1.46 <0.001 1.23 1.06, 1.40
Signiﬁcant Controlled Direct Effect Associated With a Decreased Risk of MS
rs7599312 2 ERBB4 0.77 0.62, 0.97 <0.001 0.91 0.78, 1.09 0.01 0.85 0.71, 0.98
Abbreviations: BMI, body mass index; CI, conﬁdence interval; HLA, human leukocyte antigen; HLA-DRB1*15:01, *15:01 allele of the human
leukocyte antigen (HLA) antigen D–related β1 subunit (DRB1) gene; KPNC, Kaiser Permanente Medical Care Plan of Northern California; MS,
multiple sclerosis; OR, odds ratio.
aP value for logistic regression analyses that adjusted for sex, smoking status, education, birth year, HLA-DRB1*15:01 status, weighted
genetic risk score for 110 non-HLA variants related to MS risk, and genetic ancestry; for the Swedish studies, results were additionally adjusted
for study type. BMI was calculated as weight (kg)/height (m)2, and the mediator was deﬁned as BMI during young adulthood (set at 22.0). All
analyses were bootstrapped with 100 replications. Meta-analysis was conducted with bootstrapped estimates, with adjustment for random
effects.
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a relatively weak instrument (R2 for the BMI GRS was 1.5%
in the Swedish studies and 2.3% in KPNC participants),
which is in accordance with the GWAS identifying the 97
variants (reported R2 = 2.7%) (13). We were also able to
demonstrate ﬁndings in 2 data sets and conduct rigorous
quality control to account for population stratiﬁcation.
Additionally, we used the most recent data to build a BMI
GRS of 97 variants.
As with any efforts to make a causal inference from
observational data, MR analysis involves many assump-
tions, and we have addressed them to the best of our abil-
ity. We were able to meet most model assumptions by
using a BMI GRS established to be associated with BMI in
an independent population through a large GWAS, testing
whether the BMI GRS was independent of measured con-
founders, and conducting a direct effect analysis to ensure
that the BMI GRS did not contain any variants indepen-
dently associated with MS. We additionally validated our
BMI GRS by conducting overidentiﬁcation tests and by ad-
justing for BMI in our model. However, associations of
genetic variants with unmeasured or unknown confounders
cannot be ruled out, leaving one assumption not fully test-
able (39).
Our study included non-Hispanic white persons, which
limits the generalizability of our ﬁndings. Additional lim-
itations of our study include a relatively small sample of
men, an assumption of linearity, and possible pleiotropic
effects of BMI GRS on MS (i.e., genes may inﬂuence phe-
notypes other than BMI that are associated with an
increased risk of MS). We did not have serum vitamin D
concentrations and thus were not able to include this vari-
able in our statistical models. Further, the life-course speci-
ﬁcity of the BMI GRS remains to be fully understood.
Limitations of effects analysis include reliance on self-
reported weight and height to calculate BMI, which may
have biased the mediation results. We also used 2 slightly
different assessments to calculate BMI during young adult-
hood for the KPNC (weight during ages 20–29 years) and
GERA (weight at age 18 years) cohorts; however, repeated
sampling procedures in the GERA data set indicated no
signiﬁcant deviations in BMI between the 2 control sam-
ples. Additional studies should aim to replicate these ﬁnd-
ings, speciﬁcally in populations of other race/ethnicities.
In conclusion, we found that BMI is causally associated
with MS by using a BMI GRS of 97 genetic variants with an
analytical approach that avoids bias from reverse causation
and potential confounders. While BMI-related variants dem-
onstrated indirect effects on MS through their association
with increased BMI, we also found that certain variants may
directly inﬂuence MS via independent mechanisms. These
ﬁndings provide targets for future therapeutic interventions
and aid in the understanding of the complex relationship
between genetics, BMI, and the MS disease process.
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APPENDIX
Kaiser Permanente genotyping and quality control
Whole blood was collected and processed and DNA was
extracted using the Gentra Puregene (Qiagen, Hilden,
Germany) protocol. Saliva was collected using Oragene kits
(DNA Genotek Inc., Ottowa, Ontario, Canada). Medium-
resolution human leukocyte antigen (HLA) antigen D–related
β1 subunit (DRB1) gene (HLA-DRB1) and genome-wide
single-nucleotide polymorphism (SNP) genotyping was per-
formed as previously described (3, 40), using an Axiom
(Affymetrix, Santa Clara, California) custom chip for
Genetic Epidemiology Research on Aging controls and the
Illumina Inﬁnium 660K BeadChip Array (Illumina Inc.,
San Diego, California) and Human Omni Express (Illumina
Inc.) for cases and controls from the Kaiser Permanente
Medical Care Plan of Northern California. Low-quality
SNPs were removed prior to imputation (<1% minor allele
frequency, genotyped in <90% of individuals) as were
samples with more than 10% failed genotype calls, dupli-
cates, or related individuals. Imputation against reference
haplotypes from the 1000 Genomes Project (http://www.
internationalgenome.org/) was conducted using SHAPEIT
(http://www.shapeit.fr/) and IMPUTE2 (https://mathgen.
stats.ox.ac.uk/impute/impute_v2.html) (information score
>0.8 on all 3 platforms; minor allele frequency in controls
with standard deviation <3%). Cross-platform association
tests were also conducted to remove SNPs associated with
the genotype array (false-discovery-rate Q < 0.05). Popu-
lation outliers were identiﬁed using multidimensional
scaling and reference samples from the Human Genome
Diversity Project (http://www.hagsc.org/hgdp) and were
removed from the analyses.
Swedish genotyping and quality control
All participants were asked to give blood samples,
which were genotyped on an Illumina custom array and
on OmniExpress-24 (Illumina Inc.). HLA-DRB1 informa-
tion was imputed with HLA*IMP02 (Affymetrix), using
genotypes in the major histocompatibility complex region
from the custom array. SNPs with less than a 2% minor
allele frequency, genotyped in fewer than 98% of indivi-
duals, or not in Hardy-Weinberg equilibrium among con-
trols (P < 0.0001) were removed from the analysis.
Individuals with more than 2% failed genotype calls,
related individuals, or population outliers identiﬁed using
the SmartPCA program were also removed (41). Twelve
SNPs related to body mass index were taken from the
custom array, and the remaining genotypes were taken
from the OmniExpress chip. Forty-three SNPs related to
body mass index were not present on the array and were
imputed using MaCH 1.0 (42) with standard settings and
the Northern European 1000 Genomes Project reference
panel. Seventeen markers used the August 2009 reference
panel, 25 markers used the August 2010 panel, and 1
marker used the July 2011 panel.
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